Rocco Totaro, Caterina Di Carmine and Antonio Carolei
We report a case of a woman with relapsing remitting multiple sclerosis presenting with tumefactive demyelination
at disease onset and treated with natalizumab after failure of first-line drugs. Patient was shifted from natalizumab
to fingolimod treatment because of progressive multifocal leukoencephalopathy risk. Thirteen months after starting
fingolimod treatment she developed a relapse with brain MRI findings of tumefactive demyelinating lesions. We also
present a literature review on similar cases discussing a possible role of the drugs in determining brain tumefactive
lesions.